Glen Eagle Advisors, LLC Intellia Therapeutics, Inc. Transaction History
Glen Eagle Advisors, LLC
- $593 Billion
- Q3 2024
A detailed history of Glen Eagle Advisors, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 50 shares of NTLA stock, worth $736. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50
Previous 50
-0.0%
Holding current value
$736
Previous $1.12 Million
8.13%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding NTLA
# of Institutions
315Shares Held
91.5MCall Options Held
442KPut Options Held
880K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.3MShares$181 Million2.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.63MShares$142 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$141 Million0.0% of portfolio
-
State Street Corp Boston, MA5.14MShares$75.8 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.95MShares$72.9 Million3.75% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.12B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...